Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052752 · ClinicalTrials.gov registry record · Phase 4
A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT02052752 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 90 participants.
The verdict
NCT02052752, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
5 Day study to assess how quickly a topical acne product begins to work.
Interventions
- DRUG 3% Benzoyl Peroxide
- DRUG 3% Benzoyl Peroxide Placebo
- DRUG Neutrogena Rapid Clear®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052752
The ClinicalTrials.gov registry entry for NCT02052752 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 3% Benzoyl Peroxide is the first listed.
NCT02052752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052752 about?
NCT02052752 is a clinical study titled "A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions". 5 Day study to assess how quickly a topical acne product begins to work.
What is the current status of trial NCT02052752?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2014-02. Estimated completion is 2014-05.
What interventions are being tested in trial NCT02052752?
The interventions under investigation include: 3% Benzoyl Peroxide (DRUG), 3% Benzoyl Peroxide Placebo (DRUG), Neutrogena Rapid Clear® (DRUG).
Who is sponsoring clinical trial NCT02052752?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.